Chinese coronavirus vaccine approved by its military for use within ranks

Chinese COVID-19 vaccine shows promise in human trials: Details here

CanSino Biologics, a Chinese laboratory based in Shanghai, has been granted permission for its coronavirus vaccine to be used by the country's military after clinical trials proved hopeful. During a meeting of the WHO on in May, Chinese President Xi Jinping had suggested that if China produced a dependable anti Covid-19 vaccine, Beijing would make it "available to the world".

Interestingly, this is the second experimental COVID-19 vaccine from CNBG.

The Ad5-nCoV, a Covid-19 vaccine jointly developed by CanSino Biologics and the Academy of Military Medical Sciences- a medical research institute run by the People's Liberation Army, is among the eight vaccines China has approved for human trials for the respiratory disease caused by Covid-19. Now, China's Central Military Commission has approved the use of the drug by the military on June 25th for one year.

A coronavirus vaccine candidate that showed promise in the early stages of clinical trials has been approved for use with China's military.

"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said, referring to the Central Military Commission department where the military use of the vaccine was approved.

In an interview with Chemical and Engineering News, Wistar Institute scientist Hildegund C.J. Ertl, who works on adenoviral vector vaccines, said, "It is not great, but it is better than nothing".

Most of the other vaccines in the pipeline target not the whole germ but a key piece: the "spike" protein that studs the coronavirus surface and helps invade human cells.

Another vaccine made by the NIH and Moderna Inc. simply injects a part of the coronavirus genetic code that instructs the body to produce copies of harmless spikes that the immune system learns to recognize.

CanSino added that it can not guarantee the vaccine - which had its phase one and two clinical trials done in China - will ultimately be commercialised.

None have yet been approved for commercial use against the coronavirus.

The experimental shot, developed by a Beijing-based unit of CNBG, has induced high-level antibodies in all the inoculated participants in a Phase 1/2 clinical trial involving 1,120 healthy people, according to preliminary data of the trial, CNBG said in a posting on the social media platform WeChat, without disclosing specific readings.